Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENT
  • CUSIP: N/A
  • Web:
  • Market Cap: $802.74 million
  • Outstanding Shares: 28,772,000
Average Prices:
  • 50 Day Moving Avg: $27.22
  • 200 Day Moving Avg: $19.28
  • 52 Week Range: $7.65 - $29.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -59.36
  • P/E Growth: -1.93
Sales & Book Value:
  • Annual Revenue: $82.49 million
  • Price / Sales: 9.73
  • Book Value: $3.83 per share
  • Price / Book: 7.28
  • EBIDTA: ($23,420,000.00)
  • Net Margins: -28.71%
  • Return on Equity: -20.49%
  • Return on Assets: -18.29%
  • Current Ratio: 9.47%
  • Quick Ratio: 8.90%
  • Average Volume: 421,359 shs.
  • Beta: 0.78
  • Short Ratio: 1.43
Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $20.47 million for the quarter, compared to analysts' expectations of $19.39 million. Intersect ENT had a negative net margin of 28.71% and a negative return on equity of 20.49%. View Intersect ENT's Earnings History.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 brokers have issued 1-year price targets for Intersect ENT's shares. Their predictions range from $14.00 to $26.00. On average, they anticipate Intersect ENT's stock price to reach $18.78 in the next year. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (7/5/2017)
  • 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

  • Lisa D. Earnhardt, President, Chief Executive Officer, Director
  • Jeryl L. Hilleman, Chief Financial Officer
  • Richard E. Kaufman, Senior Vice President, Chief Operating Officer
  • David A. Lehman, General Counsel
  • Gwen Carscadden, Chief People Officer
  • Kieran T. Gallahue, Lead Director
  • William Anthony Vernon, Director
  • Cynthia L. Lucchese, Independent Director
  • Dana G. Mead Jr., Independent Director
  • Frederic H. Moll M.D., Independent Director

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $27.90.

MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $18.78 (32.70% downside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/31/2017Northland SecuritiesDowngradeOutperform -> Market PerformMediumView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017Canaccord GenuityReiterated RatingBuyHighView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
3/6/2017Deutsche Bank AGUpgradeHold -> Buy$15.00 -> $19.00N/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/AView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
11/2/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$25.00 -> $16.00N/AView Rating Details
8/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$21.00N/AView Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
12/18/2015Bank of America CorporationInitiated CoverageBuy$26.00N/AView Rating Details
10/2/2015Sterne Agee CRTReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Intersect ENT (NASDAQ:XENT)
Earnings by Quarter for Intersect ENT (NASDAQ:XENT)
Earnings History by Quarter for Intersect ENT (NASDAQ XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intersect ENT (NASDAQ:XENT)
2017 EPS Consensus Estimate: ($0.73)
2018 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.22)($0.24)
Q2 20173($0.19)($0.19)($0.19)
Q3 20173($0.24)($0.14)($0.20)
Q4 20173($0.14)($0.06)($0.11)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)


Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 76.12%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.30View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
DateHeadline logoTeresa L. Kline Joins Intersect ENT's Board of Directors | Business ... - Business Wire (press release) - July 21 at 8:52 AM logoTeresa L. Kline Joins Intersect ENT’s Board of Directors - July 21 at 8:51 AM logoZacks: Analysts Expect Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $22.65 Million - July 20 at 11:54 AM logoInsider Selling: Intersect ENT, Inc. (NASDAQ:XENT) Insider Sells 20,000 Shares of Stock - July 18 at 7:25 PM logo Analysts Expect Intersect ENT, Inc. (XENT) to Announce -$0.19 Earnings Per Share - July 18 at 2:42 PM logoIntersect ENT to Report Second Quarter 2017 Financial Results - July 15 at 9:46 AM logoETFs with exposure to Intersect ENT, Inc. : July 12, 2017 - July 13 at 11:17 AM logoIntersect ENT, Inc. (NASDAQ:XENT) CFO Sells $348,855.30 in Stock - July 12 at 8:17 PM logoIntersect ENT, Inc. (XENT) Downgraded to "Sell" at Zacks Investment Research - July 9 at 6:38 PM logoCommit To Buy Intersect ENT At $22.50, Earn 15.7% Annualized Using Options - July 8 at 8:54 AM logoETFs with exposure to Intersect ENT, Inc. : June 27, 2017 - June 28 at 3:32 AM logoIntersect ENT, Inc. (XENT) Given Average Rating of "Buy" by Brokerages - June 27 at 2:56 PM logoIntersect ENT, Inc. (XENT) Expected to Post Quarterly Sales of $22.65 Million - June 24 at 9:34 AM logoZacks: Brokerages Anticipate Intersect ENT, Inc. (XENT) Will Announce Earnings of -$0.19 Per Share - June 22 at 11:04 AM logoInsider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock - June 19 at 7:20 PM logoETFs with exposure to Intersect ENT, Inc. : June 16, 2017 - June 17 at 7:50 AM logoIntersect ENT, Inc. :XENT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 4:16 PM logoFinancial Survey: Intersect ENT (XENT) vs. VWR Corporation (VWR) - June 13 at 10:18 AM logoIntersect ENT Inc (XENT) Upgraded by ValuEngine to "Hold" - June 2 at 6:18 PM logoIntersect ENT Inc (XENT) Receives Average Rating of "Buy" from Analysts - June 2 at 9:00 AM logoZacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $22.65 Million - May 31 at 2:50 PM logoIntersect ENT Inc (XENT) Downgraded by Northland Securities - May 31 at 11:56 AM logo-$0.19 Earnings Per Share Expected for Intersect ENT Inc (XENT) This Quarter - May 29 at 8:28 AM logoIntersect ENT Inc (XENT) Short Interest Update - May 29 at 7:06 AM logoFY2017 EPS Estimates for Intersect ENT Inc Decreased by Leerink Swann (XENT) - May 25 at 7:42 AM logoInsider Selling: Intersect ENT Inc (XENT) COO Sells 20,000 Shares of Stock - May 23 at 7:46 PM logoIntersect ENT (XENT) Announces 01/07/18 PDUFA Date for SINUVA ... - - May 22 at 8:05 AM logoIntersect ENT Announces PDUFA Date for Office-Based SINUVA™ Steroid Releasing Sinus Implant - May 22 at 8:05 AM logoIntersect ENT Inc (XENT) Insider Sells $459,600.00 in Stock - May 16 at 7:32 PM logoIntersect ENT's (XENT) "Outperform" Rating Reiterated at William Blair - May 13 at 12:32 AM logoResearch Analysts Offer Predictions for Intersect ENT Inc's Q2 2017 Earnings (XENT) - May 12 at 7:50 AM logoIntersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages - May 8 at 11:28 AM logoIntersect ENT Inc (XENT) Expected to Announce Quarterly Sales of $22.7 Million - May 5 at 1:38 PM logoIntersect ENT Inc Expected to Post Q3 2017 Earnings of ($0.24) Per Share (XENT) - May 5 at 10:42 AM logoLeerink Swann Comments on Intersect ENT Inc's Q2 2017 Earnings (XENT) - May 5 at 7:37 AM logoIntersect ENT Inc Forecasted to Earn FY2019 Earnings of ($0.02) Per Share (XENT) - May 4 at 7:31 PM logoNorthland Securities Reiterates Outperform Rating for Intersect ENT Inc (XENT) - May 4 at 7:18 AM logoIntersect ENT's (XENT) "Buy" Rating Reaffirmed at Canaccord Genuity - May 4 at 12:06 AM logoIntersect ENT Inc (XENT) Given "Buy" Rating at Canaccord Genuity - May 4 at 12:00 AM logoNoteworthy Wednesday Option Activity: XENT, TGT, QRVO - May 3 at 7:03 PM logoZacks: Brokerages Expect Intersect ENT Inc (XENT) to Announce -$0.21 EPS - May 3 at 6:00 PM logoIntersect ENT Inc (XENT) Issues Quarterly Earnings Results - May 3 at 4:58 PM logoIntersect ENT (XENT) Receiving Somewhat Favorable Media Coverage, Report Shows - May 3 at 4:26 PM logoEdited Transcript of XENT earnings conference call or presentation 2-May-17 8:30pm GMT - May 3 at 9:37 AM logoIntersect ENT Inc (XENT) Given New $26.00 Price Target at Wedbush - May 3 at 9:06 AM logoInvestor Network: Intersect ENT Inc. to Host Earnings Call - May 2 at 6:50 PM logoIntersect ENT Reports First Quarter 2017 Results - May 2 at 6:50 PM logoIntersect ENT reports 1Q loss - May 2 at 6:38 PM logoIntersect ENT (XENT) Earning Somewhat Favorable Media Coverage, Study Finds - April 30 at 8:25 AM logoIntersect ENT to Present at Bank of America Merrill Lynch 2017 ... - Yahoo Finance - April 28 at 2:30 AM



Intersect ENT (XENT) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff